EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study

Mousab Al Abbas iD, Jabra Zarka, Alvin C Silva, Filippo Cingolani iD, Muhammed Uzair Sarfraz, Albert Jang iD, Muhammad Ali Khan, Fouad Nahhat, Winston Tan, Brian A Costello, Haidar Abdul-Muhsin, Irbaz Bin Riaz iD und 1 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag331 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2026. Verfasst von Mousab Al Abbas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, United States. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Basic Helix-Loop-Helix Proteins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Management of von Hippel–Lindau (VHL) disease is challenging due to multisystem involvement and limited systemic treatment options. Belzutifan has shown promising efficacy in clinical trials; however, real-world data remain limited. We aimed to evaluate its effectiveness and safety in a real-world cohort.

Methods

We conducted a retrospective study of 59 patients with VHL disease treated with belzutifan between August 2021 and January 2026. Objective response rates (ORR) for renal cell carcinoma (RCC), central nervous system hemangioblastomas (CNS HB), and pancreatic neuroendocrine tumors (pNET) were assessed by an independent radiologist. Retinal hemangioblastoma outcomes were evaluated through ophthalmology records by chart review.

Results

Median follow-up was 29 months. ORR was 27.6%, 39.6%, and 85.7% for RCC, CNS HB, and pNET, respectively. Among 13 patients with retinal hemangioblastomas (20 eyes), 17 eyes (85%) showed improvement. At data cutoff, 47 patients (79.6%) remained on treatment, while 12 (20.3%) discontinued (7 due to adverse events, 3 to disease progression, and 2 to other reasons). The most common adverse event was anemia (86.4%). Grade ≥3 adverse events occurred in 10 patients (16.9%). The procedure rate per patient-year decreased from 0.35 in the 3 years prior to treatment to 0.08 during follow-up (Incidence Rate Ratio, 0.23; 95% CI, 0.12-0.47; P < .001)

Conclusions

Belzutifan demonstrated efficacy across VHL-associated lesions, with a favorable safety profile. Most adverse events were grade 1-2. A reduction in procedure rate was observed after treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Hippel-Lindau DiseaseBasic Helix-Loop-Helix ProteinsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedEndothelial PAS Domain-Containing Protein 1HemangioblastomaTreatment OutcomeCarcinoma, Renal CellYoung Adult

Stichwörter der Autor:innen

HIF-2αVHL diseasebelzutifanreal-world

Substanzen

Endothelial PAS Domain-Containing Protein 1Basic Helix-Loop-Helix Proteins

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.
  • Division of Internal Medicine, University of South Alabama, Mobile, AL 36617, United States.
  • Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Rochester, Rochester, MN 55905, United States.
  • Division of Radiology, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.
  • Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL 32224, United States.
  • Division of Urology, Mayo Clinic Arizona, Phoenix, AZ 85054, United States.

ORCID-Profile: Mousab Al Abbas, Filippo Cingolani, Albert Jang, Irbaz Bin Riaz

Zitieren

APA

Al Abbas, M., Zarka, J., Silva, A. C., Cingolani, F., Sarfraz, M. U., Jang, A., Khan, M. A., Nahhat, F., Tan, W., Costello, B. A., Abdul-Muhsin, H., Bin Riaz, I., & Zakharia, Y. (2026). Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study. The Oncologist. https://doi.org/10.1093/oncolo/oyag331

Vancouver

Al Abbas M, Zarka J, Silva AC, Cingolani F, Sarfraz MU, Jang A, et al. Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study. The Oncologist. 2026. doi:10.1093/oncolo/oyag331

BibTeX
@article{AlAbbas2026,
  author = {Al Abbas, Mousab and Zarka, Jabra and Silva, Alvin C and Cingolani, Filippo and Sarfraz, Muhammed Uzair and Jang, Albert and Khan, Muhammad Ali and Nahhat, Fouad and Tan, Winston and Costello, Brian A and Abdul-Muhsin, Haidar and Bin Riaz, Irbaz and Zakharia, Yousef},
  title = {Clinical outcomes of HIF-2 α inhibition in Von Hippel–Lindau disease: a multicenter real-world study},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag331}
}
Kostenlos starten →